Share this:
February 2022
carcinoid.org about us for patients for doctors resources events news
New Survey for the NET Community
You can make a difference in how a clinical trial is designed! Share your thoughts today by participating in a new survey for neuroendocrine cancer patients with Carcinoid Syndrome.  
Naveos Biopharma Consulting is assisting a pharmaceutical company to conduct some market research on Carcinoid Syndrome. The sponsoring pharmaceutical company will be investing in clinical trials to explore new treatments for Carcinoid Syndrome and has designed a web-based survey to gather patient insights.
This confidential, online survey, available through February 12th, begins with a screening section, to determine eligibility for taking the survey. The survey takes about 10 minutes to complete. 
After the survey closes, your responses will be combined with the responses of other participants. The data will undergo a statistical analysis and will be fully anonymized (removing any data that could potentially be used to identify you during the analysis).

Please note that the survey is intended for United States patients only. Naveos Biopharma Consulting is offering $20 gift cards to thank all eligible patients who complete the entire survey.
CLICK HERE to launch the survey.
Thank you for your support!
The Carcinoid Cancer Foundation's educational, awareness and advocacy activities are made possible by your contributions. These crucial activities lead towards early detection, improving the quality of life for cancer survivors, and ultimately to a cure. The Carcinoid Cancer Foundation is a 501(c)(3) nonprofit organization. All contributions to The Carcinoid Cancer Foundation are tax-deductible to the extent allowed by law. Thank you for your support!
Carcinoid Cancer Foundation
118 North Bedford Road, Suite 100
Mount Kisco, NY 10549
Phone: 1-888-722-3132
E-Mail: carcinoid@carcinoid.org
facebook twitter You tube Blog
118 N. Bedford Road Suite 100 | Mt. Kisco, NY 10549-2555 US
powered by emma
Subscribe to our email list.